| Name | [(3aR,5R,6S,7R,7aR)-6,7-diacetyloxy-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]oxazol-5-yl]methyl acetate |
|---|---|
| Synonyms | wzfqzrlqmxzmja-kstchigdsa |
| Description | FR054 is an inhibitor of the HBP enzyme PGM3, with a remarkable anti-breast cancer effect[1]. |
|---|---|
| Related Catalog | |
| In Vitro | FR054 (0.5-1 mM, 24-48 h) induces an early proliferation arrest followed by a marked cell death increase in breast cancer cells and induces apoptosis. The effect of FR054 occurs through PGM3 inhibition instead of other off-target effects[1]. FR054 (250 μM, 24 h) treatment efficiently affects both N- and O-glycosylation levels in MDA-MB-231 cells[1]. FR054 induces endoplasmic reticulum (ER) stress and a ROS-dependent apoptotic cell death[1]. Cell Viability Assay[1] Cell Line: MDA-MB-231 cells. Concentration: 0.5-1 mM. Incubation Time: 48 h. Result: Reduced viability and a significant increase of the apoptosis as compared to the control clone. |
| In Vivo | FR054 (1000 mg/kg, ip) suppresses cancer growth in MDA-MB-231 xenograft mice[1]. Animal Model: Mice were subcutaneously injected with MDA-MB-231 cells[1]. Dosage: 1000 mg/kg. Administration: IP, single or fractionated dose (twice a day 500 mg/kg/dose). Result: Appears to have an in vivo antitumor efficacy that is higher when administered twice a day compared to single administration. |
| References |
| Density | 1.45±0.1 g/cm3(Predicted) |
|---|---|
| Boiling Point | 416.7±45.0 °C(Predicted) |
| Molecular Formula | C14H19NO8 |
| Molecular Weight | 329.30 |
| Exact Mass | 329.11100 |
| PSA | 109.72000 |
| Hazard Codes | Xn |
|---|